A Phase 1 interventional study of DWP16001 and DWC202001+DWC202002 in Healthy, sponsored by Daewoong Pharmaceutical Co. LTD.. Status unknown at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-27.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate drug-drug interaction by comparing the pharmacokinetics (PK)/pharmacodynamics (PD), safety, and tolerability of single/multiple doses of DWP16001 , DWC202001 and DWC202002 alone or in combination in healthy male adults.
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: DWP16001
Drug: DWC202001+DWC202002
Drug: DWP16001+DWC202001+DWC202002
Tablets, Oral, once daily single dose
Tablets, Oral, multiple doses of DWC202001 and DWC202002 in combination
Drug page: Enavogliflozin
Tablets, Oral, DWP16001 , DWC202001 and DWC202002 in combination
Cmax of DWP16001
Peak Plasma Concetration
Time frame: 0-72 hours
AUClast of DWP16001
Area under the plasma concentration versus time curve
Time frame: 0-72 hours
Cmax,ss of DWC202001 and DWC202002
Peak Plasma Concetration at steady-state
Time frame: 0-72 hours
AUCτ,ss of DWC202001 and DWC202002
Area under the plasma concentration versus time curve at Tau, steady-state
Time frame: 0-72 hours
Tmax of DWP 16001, DWC202001 and DWC202002
Time at Cmax
Time frame: 0-72 hours
T1/2 of DWP 16001, DWC202001 and DWC202002
Time frame: 0-72 hours
CL/F of DWC202001 and DWC202002
Time frame: 0-72 hours
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2020; primary completion for Jul 2020, 3 months later.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enavogliflozin
Daewoong Pharmaceutical Co. LTD. →